Alterity Therapeutics Ltd has released a press release.
Expanded ATH434 Phase 2 Clinical Development Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Form 20-F
- Appendix 4E & Annual Report 2021
- New US Patent Expands Neurodegeneration Treatment Portfolio
- New Publication Demonstrates ATH434 is Neuroprotective
- New US patent targeting major neurodegenerative diseases
Later from Alterity Therapeutics
- New Data Advance ATH434 as Neurodegeneration treatment
- Chairmans Address 2021 Annual General Meeting
- ATH Annual General Meeting Presentation
- First Regulatory Authorization to Proceed with Phase 2 Trial
- New US Patent for Compounds to Treat Neurodegeneration
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics